Researcher:
Öztürk, Erman

Profile Picture
ORCID

Job Title

Doctor

First Name

Erman

Last Name

Öztürk

Name

Name Variants

Öztürk, Erman

Email Address

Birth Date

Filters

2015 - 201916

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.8662bf7b-9ca0-4a98-9289-50a2492cf123

Search Results

Now showing 1 - 10 of 16
  • Placeholder
    PublicationMetadata only
    A practical and case-based approach to thrombocytopenia in cardiology practice
    (Turkish Soc Cardiology, 2018) N/A; N/A; Öztürk, Erman; Mutluer, Ferit Onur; Doctor; Faculty Member; School of Medicine; N/A; Koç University Hospital; N/A; N/A; N/A
    In cardiology practice, anticoagulation and antiplatelet therapies are essential for most patients. As of yet, there is no high quality evidence regarding these treatments in thrombocytopenic patients, which continues to be an issue. Thrombocytopenia is defined as a platelet count of <150x10(9)/L and is classified as severe when the platelet count is <50x10(9)/L. Pseudothrombocytopenia, drug-induced thrombocytopenia, immune thrombocytopenia, heparin-induced thrombocytopenia, and thrombotic thrombocytopenic purpura are some of the main causes of thrombocytopenia. The current treatment suggestions are conservative, as a result of the lack of evidence, built on defensive treatment strategies and the fear of bleeding complications. Many patients with acute myocardial infarction with thrombocytopenia have undergone percutaneous coronary intervention successfully with adjunctive antiplatelet and anticoagulant use, as has been described in case reports. A risk-benefit ratio should be evaluated for antiplatelet therapy. In the relevant guidelines, while full dose low-molecular-weight heparin (LMWH) is recommended for patients with a thrombocyte count of >50x10(9)/L, a half-dose of LMWH is recommended in patients with thrombocytopenia between 25 and 50x10(9)/L. According to the current guidelines, avoiding antiplatelet and anticoagulant treatment should be restricted to patients with very severe thrombocytopenia (i.e., a platelet count <25x10(9)/L), but new data and recommendations are needed.
  • Placeholder
    PublicationMetadata only
    Rituximab desensitization in three patients with severe rituximab allergy
    (Mosby-Elsevier, 2017) N/A; N/A; Öztürk, Erman; Özyiğit, Sabiha Leyla Pur; Öztürk, Ayşe Bilge; Akay, Olga Meltem; Çetiner, Mustafa; Ferhanoğlu, Ahmet Burhan; Doctor; Doctor; Faculty Member; Faculty Member; Faculty Member; Faculty Member; N/A; N/A; School of Medicine; School of Medicine; School of Medicine; School of Medicine; Koç University Hospital; Koç University Hospital; N/A; N/A; N/A; N/A; N/A; 214687; 147629; 170966; N/A; 18320
    Rituximab is a chimeric monoclonal antibody that targets CD20 positive B cells and has a positive effect on both overall and progression-free survival in B-cell lymphoid malignancies. Combination rituximab with chemotherapy treatment provide survival improvement. Although rituximab is an important treatment option in hematological malignancies, the risk of allergic reactions is high. These reactions are usually IgE-mediated and can be varied in regard of severity from urticaria to anaphylaxis. It is an option to interrupt the treatment and ommit rituximab therapy who had allergic reactions. Drug desensitization is another option and successful results have been reported by applying desensitization to such reactions. Drug desensitization alters the immune response to induce a state of temporary clinical tolerance to the allergic drug by giving gradual increasing of doses of drug at fixed time intervals. Herein, we present 3 cases successfully treated with rituximab desensitization. The cases were using rituximab with the diagnosis of Burkitt lymphoma, follicular lymphoma, and marginal zone lymphoma, respectively. Two cases had grade 2 and 1 case had grade 3 systemic allergic reaction with rituximab. There was no known allergy history in all 3 cases. All patients tolerated the desensitization protocol. The subsequent treatments of the patients were also given by desensitization protocol. A total of 12 desensitizations were administered to 3 cases. No severe or life-threating reactions were observed in subsequent applications. To date applying desensitization protocols ensure rituximab treatment safely. Rituximab desensitization can be performed at trained allergy centers, and it may be an appropriate option for rituximab allergic patients.
  • Placeholder
    PublicationMetadata only
    Hepatitis B virus (HBV) reactivation induced by bortezomib use and autologous bone marrow transplantation in a patient recovered from HBV infection
    (Doc Design Informatics Co Ltd, 2017) Yılmaz-Karadag, Fatma; Ergen, Pınar; Aydın, Özlem; N/A; Öztürk, Erman; Doctor; N/A; Koç University Hospital; N/A
    In hematologic malignancy patients with HBsAg positivity, the risk of hepatitis B reactivation is high in cases of high dose use of corticosteroids, rituximab, chemotherapy agents belonging to the anthracycline group and stem cell transplantation. HBV reactivation has been reported in the literature generally in HBsAgnegative, anti-HBc IgG- and anti-HBs-positive lymphoma patients in case of stem cell transplantation or use of rituximab as a chemotherapeutic agent. There are publications that report cases of HBV reactivation in HBsAg-negative multiple myeloma patients who have recieved bortezomib and/or stem cell. In this article, we present a multiple myeloma case with full recovery from HBV infection developing an acute hepatitis due to HBV reactivation after bortezomib use and autologous bone marrow transplantation. Finally, it was successfully treated with lamivudine. It is aimed to draw attention to the fact that hepatitis B serologic markers should be closely monitored for possibility of reactivation of hepatitis in candidates of chemotherapy/stem cell transplantation recovering from HBV infection.
  • Placeholder
    PublicationMetadata only
    The role of atopy in the pathogenesis of bleomycin pulmonary toxicity
    (W B Saunders Co Ltd, 2019) Atas, Esin Cetin; Deniz, Gunnur; N/A; Özyiğit, Sabiha Leyla Pur; Şenbaş, Zarif Asucan; Öztürk, Ayşe Bilge; Öztürk, Erman; Ergönül, Önder; Tabak, Levent; Ferhanoğlu, Ahmet Burhan; Çetiner, Mustafa; Doctor; Undergraduate Student; Faculty Member; Doctor; Faculty Member; Faculty Member; Faculty Member; Faculty Member; N/A; School of Medicine; School of Medicine; N/A; School of Medicine; School of Medicine; School of Medicine; School of Medicine; Koç University Hospital; N/A; N/A; Koç University Hospital; N/A; N/A; N/A; N/A; 214687; N/A; 147629; N/A; 110398; 167625; 18320; N/A
    Introduction: Bleomycin pulmonary toxicity (BPT) is a potentially life-threatening consequence of bleomycin usage in patients. An overproduction of epithelium-derived cytokines, habitually linked to allergic inflammation, has been recently revealed in experimental models of BPT. Methods: We assessed retrospectively our cohort of patients with Hodgkin Lymphoma treated with bleomycin between 2014 and 2016 for their demographic, clinical features, including BPT development, atopy status and risk factors for BPT. Then they were invited for allergy testing and blood sample collection. The samples were stimulated with different stimuli (Bleomycin, IL-33, TSLP) for 24 h on cell culture. The culture supernatants were analysed for TGF-beta, Galectin3, Arginin, Amphiregulin, Eotaxin, IFN gamma, TNF alpha, IL1 beta, 4, 5, 6, 10, 13, 17, MIP-1 alpha, and bleomycin hydrolase (BLH) levels. Results: The cohort consisted of 51 patients showed that atopy was the only significant risk factor for BPT occurrence (OR: 7.2, p=0.007). Fourteen subjects were included for blood analysis. The analysis of supernatants at the unstimulated condition revealed that BLH and Amphiregulin were significantly lower in patients who had BPT than controls. The BLH cut-off that best identified a history of BPT was 175.31 (Sensitivity: 62.5%, specificity: 100%). Following the stimulation, BLH reduced compared to the unstimulated condition and the difference between groups remained significant (p < 0.05). Conclusion: Our study is the first to report that low levels of bleomycin hydrolase in allergic individuals may be predisposing to a possible pathway of fibrosis.
  • Placeholder
    PublicationMetadata only
    Venetoclax-rituximab in chronic lymphocytic leukemia
    (Massachusetts Medical Society (MMS), 2018) Özbalak, Murat; N/A; N/A; Ferhanoğlu, Ahmet Burhan; Öztürk, Erman; Faculty Member; Doctor; School of Medicine; N/A; Koç University Hospital; 18320
    N/A
  • Placeholder
    PublicationMetadata only
    Use of fluorodeoxyglucose positron emission tomography for diagnosis of bleomycin-induced pneumonitis in hodgkin lymphoma
    (Taylor & Francis, 2017) Gümüş, Terman; Örnek, Serdar; Özbalak, Murat; Çetiner, Mustafa; Falay, Fikri Okan; Demirkol, Mehmet Onur; Öztürk, Erman; Ferhanoğlu, Ahmet Burhan; Bölükbaşı, Yasemin; Faculty Member; Teaching Faculty; Faculty Member; Doctor; Faculty Member; Faculty Member; School of Medicine; School of Medicine; School of Medicine; N/A; School of Medicine; School of Medicine; Koç University Hospital; N/A; 246484; 196946; N/A; 18320; 216814
    Bleomycin is an antineoplastic agent causing fatal pulmonary toxicity. Early diagnosis of bleomycin-induced pneumonitis is crucial to prevent irreversible damage. Pulmonary function tests are unreliable for identifying risk of bleomycin toxicity. Fluorodeoxyglucose PET/CT scanning can reveal inflammation secondary to pneumonitis but is not sufficiently specific for diagnosis. We retrospectively analyzed scans from 77 patients with Hodgkin lymphoma (median age 41 years, mean bleomycin dose 134 mg) to evaluate bleomycin-induced pneumonitis. We identified 13 patients with abnormal lung uptake of fluorodeoxyglucose. Tracer activity was predominantly diffuse, bilateral, in the lower lobes and subpleural areas. Interim scanning during treatment revealed pneumonitis in eight of 13 patients (asymptomatic in six). One asymptomatic patient died of bleomycin toxicity. For remaining 12 patients, bleomycin was discontinued and methylprednisolone given, all showed resolution of the pneumonitis. These findings suggest that routine interim or end-of-treatment FDG-PET/CT scanning could be beneficial for alerting clinicians to asymptomatic bleomycin-induced toxicity.
  • Placeholder
    PublicationMetadata only
    Azacitidine versus decitabine in patients with refractory anemia with excess blast-results of multicenter study
    (Elsevier, 2016) Salim, Ozan; Toptas, Tayfur; Avsar, Esin; Yucel, Orhan Kemal; Geduk, Ayfer; Mehtap, Ozgur; Tombak, Anil; Tiftik, Eyup Naci; Deveci, Burak; Kurtoglu, Erdal; Kara, Osman; Atagunduz, Isik Kaygusuz; Tuglular, Tulin Firatli; Undar, Levent; N/A; Öztürk, Erman; Ferhanoğlu, Ahmet Burhan; Doctor; Faculty Member; N/A; School of Medicine; Koç University Hospital, N/A; N/A; 18320
    The present study aimed to compare the efficacy and safety of azacitidine and decitabine in patients with myelodysplastic syndrome (MDS). A total of 88 patients diagnosed with refractory anemia with excess blast (RAEB) treated with azacitidine (n = 57) or decitabine (n = 31) were evaluated. Comparisons between azacitidine and decitabine groups were performed in the whole cohort, and in a 1:1 propensity score-matched cohort in order to reduce the simple selection bias. Patients who received azacitidine or decitabine had comparable overall response rates in both the unmatched (49.1% vs. 64.5%, p = 0.166) and the propensity-matched cohorts (52% vs. 68%, p = 0.248). The cumulative incidence of AML transformation at one year was comparable between azacitidine and decitabine in the unmatched (24.0% vs. 31.3%, p = 0.26) and in the propensity-matched cohorts (18.7% vs. 31.5%, p = 0.11). There was no difference in terms of transfusion requirement, febrile neutropenia episodes or the need for antifungal use during the treatment cycles in the propensity-matched cohort. The median overall survival was 20.4 months for azacitidine and 16.8 months for decitabine (p = 0.59). Finally, we found that at least a four-cycle treatment with any HMA was a favorable factor. In conclusion, both azacitidine and decitabine have similar efficacy and toxicity profiles in the treatment of MDS-RAEB.
  • Placeholder
    PublicationMetadata only
    Adult philadelphia chromosome-positive acute lymphoblastic leukemia in daily practice: a multicenter experience
    (Elsevier, 2016) Tekgunduz, Emre; Goker, Hakan; Kaynar, Leylagul; Sari, Ismail; Pala, Cigdem; Dogu, Mehmet Hilmi; Turgut, Burhan; Korkmaz, Serdal; Tetik, Aysegul; Buyukasik, Yahya; Hacioglu, Sibel Kabukcu; Bozdag, Sinem Civriz; Ozdemir, Evren; Altuntas, Fevzi; N/A; Öztürk, Erman; Doctor; N/A; Koç University Hospital; N/A
    In this retrospective, multicenter study, we evaluated the real-life outcomes of adult Philadelphia-positive acute lymphoblastic leukemia patients. The best results in terms of survival are achieved in patients who were treated with tyrosine kinase inhibitors during induction and received allogeneic hematopoietic cell transplantation as part of consolidation. Background: The prognosis of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) is generally poor. Currently, allogeneic hematopoietic cell transplantation (allo-HCT) is the only accepted therapy with curative potential. Patients and Methods: Herein, we report our multicenter, retrospective experience with 46 (23 female; 23 male) Ph+ ALL patients, who were treated off-study between 2005 and 2012. Results: The median age of the patients was 46 years (range, 19-73 years). During induction, 30 (65%), 13 (28%), and 3 (7%) patients received tyrosine kinase inhibitors (TKIs) concurrent with chemotherapy (TKIs/chemotherapy), chemotherapy only, and TKIs only, respectively. Following induction, rates of complete remission (CR) of the study population were 85% (n = 39). CR rate in patients receiving TKIs during induction (n = 33) was significantly higher compared with patients who received chemotherapy only (n = 13; P = .011). Taking TKIs during induction significantly reduced induction mortality (3.3% vs. 38%; P = .01). Allo-HCT was performed subsequently in 21 (46%) patients. More patients who received TKIs with or without chemotherapy (19/33; 58%) during induction were able to undergo to allo-HCT compared with patients who received chemotherapy only (2/13; 15%; P = .005). Median overall survival of patients who were treated with TKIs during induction and received allo-HCT (not reached; NR) was significantly prolonged compared with patients who received allo-HCT but without TKIs during induction (23.2 months) and to the rest of the cohort (21.2 months; P = .019). Conclusions: Current state-of-the art management of Ph+ ALL in real-life seems to be incorporation of TKIs to chemotherapy regimens and proceeding to allo-HCT, whenever possible.
  • Placeholder
    PublicationMetadata only
    Recognizing pinch purpura as the first manifestation of light-chain amyloidosis
    (Galenos Yayincilik, 2018) N/A; N/A; Öztürk, Erman; Akay, Olga Meltem; Ferhanoğlu, Ahmet Burhan; Doctor; Faculty Member; Faculty Member; N/A; School of Medicine; School of Medicine; Koç University Hospital; N/A; N/A; N/A; 170966; 18320
    N/A
  • Placeholder
    PublicationMetadata only
    Letter: monoclonal gammopathy of HEV infection. When is it significant?
    (Wiley-Blackwell, 2015) N/A; N/A; Öztürk, Erman; Baran, Bülent; Doctor; Faculty Member; N/A; School of Medicine; Koç University Hospital; N/A; 167583
    N/A